RADIOTRACER RECEIVES PRECLINICAL VALIDATION

摘要

Oncodesign has unveiled the preclinical validation of its first radiotracer prior to human application, developed as part of the IMAkinib project. Initiated in 2009, the IMAkinib project, led by Oncodesign, is a strategic industrial innovation program sponsored by Bpifranee. Dedicated to the development of novel imaging radiotracers for oncology, IMAkinib aims to find diagnostic solutions that will help select treatments best suited to individual patients, and monitor the treatment's efficacy thereafter. Within the IMAkinib project, radiotracers are expected to be developed up to the end of phase IIa.